Europe
Despite a temporary pause on its COVID-19 vaccine trial, AstraZeneca Chief Executive Officer Pascal Soriot said the preventative drug could still be available for commercial use by the end of the year, or in early 2021 barring any other setback.
Biopharma and life sciences companies bolster their leadership teams and boards with these Movers & Shakers.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 11, 2020.
GlaxoSmithKline’s Trelegy Ellipta won regulatory approval for the treatment of asthma in patients aged 18 years and older. Here’s what you need to learn.
In July, the study was paused after another patient experienced neurological issues.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Preclinical data for Pfizer and BioNTech’s Phase II/III COVID-19 mRNA vaccine candidate generated BNT162b2 strong anti-viral effects against an infectious SARS-CoV-2 challenge.
This morning, Dublin-based Amryt said the primary endpoint of the late-stage study was met. Look at what else the phase III trial of Filsuvez depicted.
AstraZeneca paused its Phase III COVID-19 vaccine trial following a report of an “unexplained illness” in a patient involved in the study.
The transaction, which is set to conclude in early 2021, will give Grifols access to Alkahest’s four product candidates.
PRESS RELEASES